"That pan-tumor approval and this patient case really highlight that in prostate cancer, we should be checking HER2 by immunohistochemistry," says Maneesh R. Jain, MD.
Maneesh R. Jain, MD
Advertisement
Articles by Maneesh R. Jain, MD
Advertisement
Latest Updated Articles
The potential of HER2 targeting in prostate cancer: A case study with trastuzumab deruxtecanPublished: December 4th 2024 | Updated:
Advertisement
Advertisement
Trending on Urology Times
1
NDV-01 produces robust 9-month results in high-risk NMIBC
2
CORE-008: Cretostimogene achieves high CR rate in high-risk NMIBC
3
Gemcitabine intravesical system delivers high 12-month DFS in papillary-only NMIBC
4
SUO 2025 data confirm IsoPSA accuracy independent of mpMRI use
5
